Focused On-demand Library for Synaptotagmin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6XYQ8

UPID:

SYT10_HUMAN

Alternative names:

Synaptotagmin X

Alternative UPACC:

Q6XYQ8; Q495U2

Background:

Synaptotagmin-10, alternatively known as Synaptotagmin X, plays a pivotal role as a Ca(2+) sensor essential for the Ca(2+)-dependent exocytosis of secretory vesicles containing IGF1 in olfactory bulb neurons. This process is crucial for the sensory perception of smell. It operates through Ca(2+) and phospholipid binding to the C2 domain, facilitating exocytosis by inducing binding of the C2-domains to phospholipid membranes and assembled SNARE-complexes.

Therapeutic significance:

Understanding the role of Synaptotagmin-10 could open doors to potential therapeutic strategies, particularly in enhancing sensory perception or addressing disorders related to olfactory functions.